Meta AnalysisID 16
黄花蒿舌下免疫治疗季节性过敏性鼻炎的疗效与安全性：随机对照试验的系统评价与Meta分析
CRD42022338850
Does Artemisia Annua sublingual immunotherapy play an effective role in the treatment of seasonal allergic rhinitis (SAR)?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 16
- Evidence Id
- 8574
- Core Evidence Id
- 8574
- Source Meta Analysis Id
- 15
- Herb2 Meta Analysis Id
- HBMA000015
- Crd Id
- CRD42022338850
- Title
- Efficacy and safety of Artemisia Annua sublingual immunotherapy in seasonal allergic rhinitis: a systematic review and meta-analysis of randomised controlled trials
- Review Question
- Does Artemisia Annua sublingual immunotherapy play an effective role in the treatment of seasonal allergic rhinitis (SAR)?
- Study Type Included
- Systematic reviews (and Meta-analysis, if available) of observational and interventional studies.
- Condition Being Studied
- The prevalence of AR has increased year by year, imposing a significant burden on socio-economics. Recently, Artemisia annua Allergen Sublingual Immunotherapy Drops have been available in the Chinese market and they have been tested and found to be effective and safe in the treatment of patients with SAR with or without allergic conjunctivitis in a series of RCTS conducted by Luo Zhang (2017) ’s team. In the research, we aim to evaluate the efficacy and safety of Artemisia allergen sublingual immunotherapy in patients with SAR and provide further evidence for SAR treatment strategies.
- Participant
- Inclusion: patients with a confirmed diagnosis of SAR, who did not receive allergen immunotherapy (AIT). Exclusion: patients with SAR who received AIT before.
- Animal
- Human Disease Modelled
- Intervention
- Artemisia annua Allergen Sublingual Immunotherapy Drops were used for the treatment of SAR.
- Comparator Control
- Comparator(s)/control: placebo or no treatment. Comparison pairs: Artemisia annua Allergen Sublingual Immunotherapy Drops versus placebo or no treatment.
- Main Outcome
- The primary outcomes of our study contained two aspects, including the total nasal symptom score (TNSS), the combined symptom, the medication score (CSMS), the combined score of medication and the rhinoconjunctivitis symptom (CSMRS), which were for evaluating the efficacy, and the safety were evaluated by serious adverse events report. Measures of effect Absolute and relative risks for the outcomes outlined above were displayed using forest plots and calculated using random effects models.
- Outcome Measure
- Additional Outcome
- Daily total nasal symptom score (dTNSS); Daily rescue medication score (dRMS); total medication score (TMS), visual analog score (VAS); Serious Adverse Events (SAEs), and Adverse Events (AEs). Measures of effect Absolute and relative risks for the outcomes outlined above; and reported hazard ratios and 95% confidence intervals (CIs).
- Study Method
- Systematic review
- Keyword
- Artemisia annua; Desensitization, Immunologic; Humans; Randomized Controlled Trials as Topic; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Sublingual Immunotherapy
- Contact
- Jia Huang [email protected]
- Organisational Affiliation
- Affiliated Hospital of Guangdong Medical University https://www.sshospital.cn
- Funding Source
- No funding sources
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-06-10
- Registration Date
- 2022-06-21
- Anticipated Start Date
- 2022-06-10
- Anticipated Completion Date
- 2022-09-25
- Title Cn
- 黄花蒿舌下免疫治疗季节性过敏性鼻炎的疗效与安全性：随机对照试验的系统评价与Meta分析
- Title En
- Efficacy and safety of Artemisia Annua sublingual immunotherapy in seasonal allergic rhinitis: a systematic review and meta-analysis of randomised controlled trials
- Bilingual Status
- complete